Welcome to our dedicated page for Haleon SEC filings (Ticker: HLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Haleon plc (HLN) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on both the London Stock Exchange and the New York Stock Exchange. Haleon files annual reports on Form 20-F and submits current reports on Form 6-K under the Securities Exchange Act of 1934. These filings cover topics such as trading statements, total voting rights and capital, board and committee changes, and transactions by persons discharging managerial responsibilities (PDMRs).
Recent 6-K filings include announcements on Haleon’s Q3 trading statement, regular updates on total voting rights and capital, and detailed notifications of share transactions under the company’s share reward plans by senior managers. Other filings describe governance developments, such as the appointment of a new Chair, changes to the Senior Independent Director role and committee memberships, and the evolution of Haleon’s operating model, including the creation of six Operating Units and new executive roles like Chief Growth Officer and Chief Transformation Officer.
Many filings contain an "About Haleon" section that reiterates the company’s profile as a global leader in consumer health with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other, along with examples of long-standing brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren.
On this page, investors can review Haleon’s SEC submissions as they are made available from EDGAR, while AI-powered tools on the platform can help summarise key points, highlight changes over time and surface information on areas such as capital structure, insider share dealings disclosed as PDMR transactions, and updates to the company’s governance and operating model.
Haleon plc (LSE/NYSE: HLN) filed a Form 6-K reporting progress on the share buyback programme announced 28 March 2025.
Daily trade: on 25 June 2025 the company repurchased 1,006,111 ordinary shares at a volume-weighted average price of 383.38 pence (high 384.80 p, low 380.70 p). All shares will be cancelled.
Completion of first tranche: Haleon has now finished the programme’s first tranche, acquiring 51,036,522 shares for an aggregate consideration of about £200 million. The tranche equates to roughly 0.6 % of the current share base.
Updated share capital: issued share capital is 8,988,533,553 shares of £0.01 each. After deducting 4,080,205 treasury shares, voting shares total 8,984,453,348. Investors should use this figure for FCA disclosure-threshold calculations.
Next steps: management will announce any further tranches separately. The filing contains no earnings, guidance, or operational updates.
Haleon has announced a significant share buyback transaction as part of its program launched on March 28, 2025. On June 23, 2025, the company purchased 1,008,610 ordinary shares for cancellation at prices ranging from 381.50p to 387.90p per share, with a volume-weighted average price of 385.10p.
Following the transaction, Haleon's registered share capital consists of 8,990,548,799 ordinary shares, with 4,080,205 held as treasury shares. The total number of voting rights is now 8,986,468,594, a figure relevant for shareholder disclosure requirements under FCA regulations.
Haleon, a global consumer health leader listed on LSE/NYSE (HLN), maintains a portfolio across six major categories including Oral Health, VMS, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Key brands include Advil, Centrum, Sensodyne, and Voltaren.
Haleon has announced a significant share buyback transaction as part of its program announced on March 28, 2025. On June 20, 2025, the company purchased 1,016,186 ordinary shares for cancellation at prices ranging from 382.70p to 388.00p per share, with a volume-weighted average price of 385.10p.
Following the settlement, Haleon's registered share capital consists of 8,991,557,409 ordinary shares of £0.01 each, with 4,080,205 held as treasury shares. The total number of voting rights is now 8,987,477,204.
Haleon, a global consumer health leader listed on LSE/NYSE, maintains a portfolio across six major categories:
- Oral Health
- Vitamins, Minerals and Supplements (VMS)
- Pain Relief
- Respiratory Health
- Digestive Health
- Therapeutic Skin Health
The company's brand portfolio includes notable names such as Advil, Centrum, Sensodyne, and Voltaren.
Haleon has reported a significant share buyback transaction as part of its program announced on March 28, 2025. On June 19, 2025, the company purchased 1,011,111 ordinary shares for cancellation at prices ranging from 382.80p to 384.90p per share, with a volume-weighted average price of 383.82p.
Following this transaction, Haleon's registered share capital consists of 8,992,573,595 ordinary shares, with 4,080,205 held as treasury shares. The total number of voting rights is now 8,988,493,390, a figure relevant for shareholders' disclosure requirements under FCA rules.
Haleon, a global consumer health leader listed on LSE/NYSE (HLN), maintains a portfolio across six major categories:
- Oral Health
- Vitamins, Minerals and Supplements
- Pain Relief
- Respiratory Health
- Digestive Health
- Therapeutic Skin Health
On 19 June 2025, Haleon plc (LSE/NYSE: HLN) filed a Form 6-K reporting activity under the share buyback programme launched on 28 March 2025. On 18 June 2025 the company repurchased 1,009,204 ordinary shares of £0.01 each for cancellation.
Key transaction metrics
- Shares purchased: 1,009,204
- Price range: 382.90 p – 386.70 p
- Volume-weighted average price: 384.87 p
- Purpose: Cancellation under authorised Buyback Programme
Post-settlement, registered share capital totals 8,993,584,706 ordinary shares, of which 4,080,205 are held in treasury. The resulting number of ordinary shares with voting rights is 8,989,504,501. Investors should apply this updated figure when assessing FCA disclosure thresholds.
A trade-by-trade schedule, published to comply with Article 5 of the UK Market Abuse Regulation, is available via the London Stock Exchange link provided. The filing reiterates that the announcement is not an offer to sell or solicit securities and supplies contact details for investor and media enquiries.